Abu Dhabi has become the first place globally to deliver ITVISMA gene therapy for spinal muscular atrophy, marking a major healthcare milestone and reinforcing the emirate's role as a leader in genomics, precision medicine, and advanced treatments.
The Emirates Drug Establishment (EDE) has announced the approval of Itvisma (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular atrophy (SMA) in eligible adults and children aged two years and above.